A New Oral Cholesterol-Lowering Pill: What Enlicitide (LIPFENDRA) Means for Heart Disease Prevention
Lowering LDL cholesterol is one of the most established and effective ways to reduce the risk of heart attack and stroke. For most people, statins remain the first-line treatment, and they work well. But a meaningful number of patients either cannot tolerate statins, do not reach their target LDL levels on statins alone, or carry a genetic condition that keeps their cholesterol dangerously high despite treatment.
For these individuals, a powerful class of medications called PCSK9 inhibitors has been available for several years, but only as injections. That may be about to change. On July 16, 2026, the U.S. Food and Drug Administration (FDA) approved enlicitide (brand name LIPFENDRA), the first oral PCSK9 inhibitor, a once-daily pill.
Important note for our Canadian patients: enlicitide is not currently approved or available in Canada. This article is intended to explain what this medication is, how it works, and why it matters, so that you are informed as this therapy develops. We will update our patients if and when it becomes available here.
What Are PCSK9 Inhibitors?
To understand why this approval matters, it helps to understand how the body clears cholesterol.
Your liver removes LDL cholesterol (often called "bad cholesterol") from the blood using structures called LDL receptors. A protein called PCSK9 breaks down these receptors. The more PCSK9 activity you have, the fewer LDL receptors remain available, and the higher your LDL cholesterol climbs.
PCSK9 inhibitors work by blocking this protein. With PCSK9 out of the way, more LDL receptors stay on the surface of liver cells, pulling more LDL cholesterol out of the bloodstream. The result is a substantial reduction in LDL, typically on the order of 50 to 60 percent, comparable to what the injectable versions achieve.
Until now, every approved PCSK9 inhibitor required an injection. The injectable antibodies (such as evolocumab and alirocumab) are given every two to four weeks, and a related therapy (inclisiran) is given twice a year. These are effective, but injections are a barrier for some patients.
What Makes Enlicitide Different
Enlicitide is a novel macrocyclic peptide designed to deliver antibody-like LDL lowering in the form of a once-daily 20 mg pill. It is the first PCSK9 inhibitor that can be taken orally.
The approval was supported by Merck's large CORALreef clinical trial program, which studied more than 19,000 participants with high cholesterol. Three pivotal trials informed the approval:
CORALreef Lipids. This trial randomized 2,909 adults with, or at risk for, atherosclerotic cardiovascular disease, most of whom were already on a statin. At 24 weeks, enlicitide reduced LDL cholesterol by roughly 57 percent compared with placebo, and the effect was sustained through one year.¹ More than two-thirds of participants reached aggressive guideline-based LDL targets.² Enlicitide also lowered other atherogenic markers, including non-HDL cholesterol, apolipoprotein B (ApoB), and lipoprotein(a), or Lp(a) — markers we have written about previously as important, often-overlooked predictors of cardiovascular risk.¹
CORALreef HeFH. In adults with heterozygous familial hypercholesterolemia (an inherited condition causing very high LDL from an early age), enlicitide reduced LDL by approximately 59 percent versus placebo at 24 weeks.³
CORALreef AddOn. When added to background statin therapy, enlicitide outperformed other commonly used oral non-statin options (ezetimibe, bempedoic acid, and their combination) for lowering LDL and ApoB.⁴
Across these trials, the safety profile was comparable to placebo, with the most commonly reported side effects being mild, such as diarrhea and dizziness, and low discontinuation rates.³
An Important Caveat: What We Don't Yet Know
Enlicitide's approval is based on its ability to lower LDL cholesterol and related markers — what researchers call surrogate endpoints. These are strong, well-validated predictors of cardiovascular risk, and decades of evidence tell us that lowering LDL reduces heart attacks and strokes.
However, a dedicated cardiovascular outcomes trial (CORALreef Outcomes) is still ongoing and is not expected to report until around 2029. Until then, we will not have direct proof that this specific pill reduces heart attacks, strokes, and cardiovascular death, only that it lowers the markers strongly associated with those events.⁵ This is a reasonable and common regulatory pathway, but it is an honest limitation worth understanding.
Why This Matters for Longevity Medicine
At LifespanMD, cardiovascular disease prevention is a cornerstone of what we do. Heart disease remains the leading cause of death worldwide, and lowering LDL cholesterol and ApoB early and effectively is one of the highest-return strategies we have for protecting long-term health.
The arrival of an oral PCSK9 inhibitor is significant for a few reasons:
Adherence. A daily pill is easier for many people to sustain than an injection, and consistent, long-term LDL lowering is what drives risk reduction.
Access for statin-intolerant patients. For those who genuinely cannot tolerate statins, an effective oral alternative expands the options.
Reaching aggressive targets. For higher-risk patients who need LDL and ApoB driven well below standard thresholds, this class provides powerful additional lowering.
That said, medication is only one part of the picture. Our approach always begins with precise measurement — including advanced markers such as ApoB and Lp(a) — followed by a plan built around nutrition, exercise, metabolic health, and, when appropriate, medication. Powerful new tools work best inside a well-monitored, individualized prevention strategy.
The Bottom Line
Enlicitide (LIPFENDRA) represents a genuine milestone: the first once-daily oral PCSK9 inhibitor, offering injectable-level LDL lowering in pill form. It is an encouraging development for the future of cardiovascular prevention.
For now, though, it is approved only in the United States and is not available in Canada. There is no publicly announced Health Canada submission at this time, and even after a filing, Canadian availability would follow the usual regulatory and reimbursement review process, which typically takes considerable time.
In the meantime, effective, Health Canada–approved options for lowering LDL cholesterol already exist, including statins, ezetimibe, injectable PCSK9 inhibitors, and inclisiran. If you are concerned about your cardiovascular risk or your cholesterol numbers, the most valuable step is a thorough, personalized assessment. Our team is always happy to review your lipid profile, discuss your options, and build a prevention plan tailored to you.
If you have questions about your cholesterol, cardiovascular risk, or how emerging therapies may fit into your prevention plan, speak with your LifespanMD physician.
References
Navar AM, Mikhailova E, Catapano AL, et al. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. New England Journal of Medicine. 2026;394(6):529–539. doi:10.1056/NEJMoa2511002.
Oral PCSK9 Inhibitor Enlicitide Lowers LDL by 57% at 24 Weeks. American Journal of Managed Care. 2026.
Merck. Enlicitide Decanoate Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial. News release. November 2025.
CORALreef AddOn: Novel PCSK9 Inhibitor Reduces LDL-C in Patients Not Meeting Goals. American College of Cardiology. March 2026.
Merck. LIPFENDRA (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia. News release. July 16, 2026.
Please Note: This article is intended for general informational purposes only and does not constitute the practice of medicine, nursing, or any other regulated health care services in Ontario. The information provided here is not medical advice, nor does it create a doctor-patient or health care provider relationship. The use of this content, or any materials linked from it, is at the reader's discretion and risk. This information is not a replacement for professional medical consultation, diagnosis, or treatment. Readers should not ignore or delay seeking medical care for any health concerns they may have and are encouraged to consult qualified health professionals for appropriate care and medical advice.
